Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Irwin

Showing results (51-60 of 161) with videos related to

Pageof 17
Sort By:
The Journal of Endocrinology|June 11, 2024
Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?Ryan A Lafferty, Peter R Flatt, Victor A Gault, et al.
Bone|July 16, 2013
Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and qualityAleksandra Mieczkowska, Nigel Irwin, Peter R Flatt, et al.
Biochemical Pharmacology|May 6, 2008
C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetesVictor A Gault, Barry D Kerr, Nigel Irwin, et al.
Biochemical Pharmacology|October 23, 2012
Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob miceNigel Irwin, Ian A Montgomery, R Charlotte Moffett, et al.
The Journal of Endocrinology|January 8, 2011
Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed miceVictor A Gault, David W Porter, Nigel Irwin, et al.
Biochimica Et Biophysica Acta|April 16, 2013
(pGlu-Gln)-CCK-8[mPEG]: a novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetesNigel Irwin, Pamela Frizelle, Finbarr P M O'Harte, et al.
Peptides|November 26, 2008
Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intoleranceBarry D Kerr, Nigel Irwin, Peter R Flatt, et al.
Frontiers in Endocrinology|May 31, 2021
Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-DiabetesNeil Tanday, Andrew English, Ryan A Lafferty, et al.
Peptides|September 15, 2022
Alpha-cells and therapy of diabetes: Inhibition, antagonism or death?Natalie Klempel, Keith Thomas, J Michael Conlon, et al.
Peptides|July 27, 2017
Differential expression of glucagon-like peptide-2 (GLP-2) is involved in pancreatic islet cell adaptations to stress and beta-cell survivalDawood Khan, Srividya Vasu, R Charlotte Moffett, et al.
Pageof 17

Showing results (51-60 of 161) with videos related to

Sort By:
Pageof 17
The Journal of Endocrinology|June 11, 2024
Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?Ryan A Lafferty, Peter R Flatt, Victor A Gault, et al.
Bone|July 16, 2013
Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and qualityAleksandra Mieczkowska, Nigel Irwin, Peter R Flatt, et al.
Biochemical Pharmacology|May 6, 2008
C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetesVictor A Gault, Barry D Kerr, Nigel Irwin, et al.
Biochemical Pharmacology|October 23, 2012
Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob miceNigel Irwin, Ian A Montgomery, R Charlotte Moffett, et al.
The Journal of Endocrinology|January 8, 2011
Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed miceVictor A Gault, David W Porter, Nigel Irwin, et al.
Biochimica Et Biophysica Acta|April 16, 2013
(pGlu-Gln)-CCK-8[mPEG]: a novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetesNigel Irwin, Pamela Frizelle, Finbarr P M O'Harte, et al.
Peptides|November 26, 2008
Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intoleranceBarry D Kerr, Nigel Irwin, Peter R Flatt, et al.
Frontiers in Endocrinology|May 31, 2021
Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-DiabetesNeil Tanday, Andrew English, Ryan A Lafferty, et al.
Peptides|September 15, 2022
Alpha-cells and therapy of diabetes: Inhibition, antagonism or death?Natalie Klempel, Keith Thomas, J Michael Conlon, et al.
Peptides|July 27, 2017
Differential expression of glucagon-like peptide-2 (GLP-2) is involved in pancreatic islet cell adaptations to stress and beta-cell survivalDawood Khan, Srividya Vasu, R Charlotte Moffett, et al.
Pageof 17